← board
LGNZZ
distress 1/10 · well-funded / low risk$0.06today0% from 52w high
Revenue
$52M
Liquidity
$779M
Runway
—
Shares 1y
+2%
Overview
- Market Cap
- $1.20M
- Volume
- 3.20K
- 52 Week Range
- $0.06 – $0.06
- Total Shares
- 20.04M
- Float Shares
- 19.53M
- RVOL
- 1.00x
- Beta
- 0.98
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2025-07-02partnershipClosed merger with Channel Therapeutics, forming Pelthos Therapeutics; shares to trade on NYSE American under PTHS.SEC 8-K
- 2025-04-16partnershipLigand's subsidiaries Pelthos and LNHC to merge with Channel Therapeutics.SEC 8-K
- 2025-02-24partnershipD-Fi (dabocemagene autoficel) · Ligand and co-investors purchase royalty and warrants for $75M to support Phase 3 trial of D-Fi for dystrophic epidermolysis bullosaSEC 8-K
- 2024-07-08partnershipdinutuximab beta · Ligand enters definitive agreement to acquire APEIRON Biologics including royalty rights to QARZIBA for high-risk neuroblastomaSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.